Company news
Hemostemix Inc news in 2021
Hemostemix Inc's news releases, calls and decks from 2021, newest first.
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
December 14, 2021
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
December 9, 2021
Hemostemix Confirms OTCQB Listing
October 28, 2021
Hemostemix Confirms OTCQB Application is Filed
October 19, 2021
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
October 14, 2021
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain
October 4, 2021
Hemostemix Announces Closing of First Tranche of Unit Private Placement
September 21, 2021
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
September 14, 2021
Hemostemix Announces Five Million Unit Private Placement
September 8, 2021
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
July 6, 2021
Hemostemix Announces Warrant Repricing and Extension
July 5, 2021
Peter Lacey Increases His Investment in Hemostemix Inc.
June 21, 2021
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
June 11, 2021
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record
May 31, 2021
Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
May 29, 2021
Hemostemix to Present at the Emerging Growth Conference
May 25, 2021
Hemostemix Announces Closing of Unit Private Placement
May 10, 2021
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
April 30, 2021
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering
April 26, 2021
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
April 23, 2021
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
April 9, 2021
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
April 8, 2021
Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities
March 18, 2021
Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
February 11, 2021
Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced
January 28, 2021
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
January 22, 2021